Cipla liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
10.87×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.44×3.44×4.24×3.70×3.34×
2.50×2.50×3.21×2.70×2.31×
7,7938,6987,8825,4473,717
18,08417,13217,76514,14711,772
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CIPLA₹1,358.00

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.10L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————10.87
Current Ratio3.343.704.243.443.44
Quick Ratio2.312.703.212.502.50
Cash, Equiv & ST Investments3,717.55,447.17,881.98,697.67,793.3
Working Capital11,771.814,146.717,765.017,132.318,083.9
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.